Focused On-demand Library for Centrosomal protein of 135 kDa

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q66GS9

UPID:
CP135_HUMAN

ALTERNATIVE NAMES:
Centrosomal protein 4

ALTERNATIVE UPACC:
Q66GS9; B2RMY0; O75130; Q58F25; Q9H8H7

BACKGROUND:
The Centrosomal protein of 135 kDa, known alternatively as Centrosomal protein 4, is integral to the early stages of centriole biogenesis. It ensures the proper targeting and recruitment of crucial satellite proteins to centrosomes and maintains centriole cohesion. Its role is further emphasized by its requirement for the recruitment of CEP295 during S phase, highlighting its importance in cellular division and integrity.

THERAPEUTIC SIGNIFICANCE:
Given its association with Microcephaly 8, primary, autosomal recessive, understanding the function of Centrosomal protein of 135 kDa is crucial. This knowledge could pave the way for developing novel therapeutic approaches targeting this protein, offering hope for treating or managing this debilitating condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 885 of 8789